Literature DB >> 22734810

Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.

Xin Zhou, Jianping Zhu, Hongli Sun, Lizheng Shao, Ming Xu, Hongfeng Guo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22734810     DOI： 10.3109/10428194.2012.701741

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

1.  Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).

Authors:  Leonard Christopher Schmeel; Frederic Carsten Schmeel; Christoph Coch; Ingo G H Schmidt-Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

Review 2.  Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.

Authors:  A Rambaldi; E Biagi; C Bonini; A Biondi; M Introna
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

3.  Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia.

Authors:  Xin-Yu Yang; Hui Zeng; Fang-Ping Chen
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

4.  Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series.

Authors:  Jingjue Mao; Feng Cheng; Heng Chen; Jing Wang; Xin Zhou; Yuanqiang Jiang; Yuanxin Zhu; Hongfeng Guo
Journal:  Exp Ther Med       Date:  2014-01-23       Impact factor: 2.447

Review 5.  Innovative Clinical Perspectives for CIK Cells in Cancer Patients.

Authors:  Martino Introna; Fabio Correnti
Journal:  Int J Mol Sci       Date:  2018-01-25       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.